SOUTH SAN FRANCISCO, Calif., Aug. 30, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (NasdaqGM:HNAB - News), a biopharmaceutical company focused on advancing cancer care, today announced the appointment of S. Michael Imperiale, Jr., M.D. as Vice President, Clinical Research Operations. Dr. Imperiale will oversee all aspects of clinical operations related to the development of Hana’s drug candidates.
``We are thrilled to have Dr. Imperiale join our team at Hana Biosciences. His proven success in clinical strategy and program management will add highly relevant expertise to our development organization as we continue to advance our pipeline of product candidates towards registration,’' stated Steven R. Deitcher, M.D., President and Chief Executive Officer.
Prior to joining Hana, Dr. Imperiale held the position of Senior Director of Medical Sciences at Nuvelo, Inc., where he was the clinical lead and strategist of the oncology program and managed the team of Medical Science Liaisons. Prior to Nuvelo, Dr. Imperiale was Director, Clinical Trials Development at Exelixis, Inc. where he was responsible for U.S. Food and Drug Administration clinical filings, building external investigator relationships, and oversight of oncology and nephrology clinical trial programs. Dr. Imperiale has also previously worked at InterMune, Inc. and Boehringer-Ingelheim Pharmaceutical Corporation. He earned a Doctor of Medicine from Hahnemann University School of Medicine and a Bachelor of Arts degree in Psychology from Villanova University.
About Hana Biosciences, Inc.
Hana Biosciences, Inc. (NasdaqGM:HNAB - News) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at http://www.hanabiosciences.com.
The Hana Biosciences, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3290
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as ``anticipates,’' ``expects,’' ``plans,’' ``believes,’' ``intends,’' and similar words or phrases. These forward-looking statements include without limitation, statements regarding the timing, progress and anticipated results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings and commercialization efforts of Hana’s product candidates. Such statements involve risks and uncertainties that could cause Hana’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana’s development efforts relating to its other product candidates will be successful, that Hana will be able to obtain regulatory approval of any of its product candidates, and that the results of clinical trials will support Hana’s claims or beliefs concerning the effectiveness of its product candidates. Additional risks that may affect such forward-looking statements include Hana’s need to raise additional capital to fund its product development programs to completion, Hana’s reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.
Contact:
Hana Biosciences, Inc. Investor & Media Contact: Remy Bernarda, Director, Investor Relations (650) 228-2769 investor.relations@hanabiosciences.com
Source: Hana Biosciences, Inc.
